Integrat Respir Med
Volume 1, 2020
Topical Issue - Integrative Respiratory Medicine for COVID-19
Article Number 1
Number of page(s) 5
Published online 29 September 2020
  • Huang X, Wei F, Hu L, Wen L, Chen K (2020), Epidemiology and Clinical Characteristics of COVID-19. Arch Iran Med 23, 4, 268–271. [CrossRef] [PubMed] [Google Scholar]
  • Greenland JR, Michelow MD, Wang L, London MJ (2020), COVID-19 Infection: Implications for Perioperative and Critical Care Physicians. Anesthesiology 132, 6, 1346–1361. [Google Scholar]
  • Lu R, Zhao X, Li J, et al. (2020), Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 10224, 565–574. [CrossRef] [PubMed] [Google Scholar]
  • Al Johani S, Hajeer AH (2016), MERS-CoV diagnosis: An update. J Infect Public Health 9, 3, 216–219. [CrossRef] [PubMed] [Google Scholar]
  • Chafekar A, Fielding BC (2018), MERS-CoV: Understanding the Latest Human Coronavirus Threat. Viruses 10, 2, 93. [Google Scholar]
  • Lin SC, Ho CT, Chuo WH, Li S, Wang TT, Lin CC (2017), Effective inhibition of MERS-CoV infection by resveratrol. BMC Infect Dis 17, 1, 144. [CrossRef] [PubMed] [Google Scholar]
  • Rabaan AA, Bazzi AM, Al-Ahmed SH, Al-Tawfiq JA (2017), Molecular aspects of MERS-CoV. Front Med 11, 3, 365–377. [Google Scholar]
  • Wu D, Wu T, Liu Q, Yang Z (2020), The SARS-CoV-2 outbreak: What we know. Int J Infect Dis 94, 44–48. [CrossRef] [PubMed] [Google Scholar]
  • Rabaan AA, Al-Ahmed SH, Haque S (2020), SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. Infez Med 28, 2, 174–184. [PubMed] [Google Scholar]
  • Xie X, Muruato A, Lokugamage KG (2020), An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe 27, 5, 841–848. [CrossRef] [PubMed] [Google Scholar]
  • Hasöksüz M, Kiliç S, Saraç F (2020), Coronaviruses and SARS-COV-2. Turk J Med Sci 50, SI-1:549–556. [Google Scholar]
  • Li H, Zhou Y, Zhang M, Wang H, Zhao Q, Liu J (2020), Updated Approaches against SARS-CoV-2. Antimicrob Agents Chemother 64, 6, e00483–20. [PubMed] [Google Scholar]
  • Bansal M (2020), Cardiovascular disease and COVID-19. Diabetes Metab Syndr 14, 247–250. [CrossRef] [PubMed] [Google Scholar]
  • Angel-Korman A, Brosh T, Glick K, Leiba A (2020), Covid-19, The kidney and hypertension. Harefuah 159, 231–234. [PubMed] [Google Scholar]
  • South AM, Diz DI, Chappell MC (2020), COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol 318, 5, H1084–H1090. [PubMed] [Google Scholar]
  • Pal R, Bhansali A (2020), COVID-19, diabetes mellitus and ACE2: The conundrum. Diabetes Res Clin Pract 162, 108132. [CrossRef] [PubMed] [Google Scholar]
  • Jakovac Hrvoje (2020), COVID-19: is the ACE2 just a foe? Am J Physiol Lung Cell Mol Physiol 318, 5, L1025–L1026. [CrossRef] [PubMed] [Google Scholar]
  • Xue J, Moyer A, Peng B, Wu J, Hannafon BN, Ding WQ (2020), Chloroquine is a zinc ionophore. PLoS One 9, 10, e109180. [Google Scholar]
  • Vincent MJ, Bergeron E, Benjannet S (2005), Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2, 69. [CrossRef] [PubMed] [Google Scholar]
  • Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D (2020), Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 55, 4, 105932. [CrossRef] [PubMed] [Google Scholar]
  • Kakodkar P, Kaka N, Baig MN (2020), A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus 12, 4, e7560. [PubMed] [Google Scholar]
  • Shukla AM, Archibald LK, Wagle Shukla A, Mehta HJ, Cherabuddi K (2020), Chloroquine and hydroxychloroquine in the context of COVID-19. Drugs Context 9, 4–5. [Google Scholar]
  • Rubin EJ, Harrington DP, Hogan JW, Gatsonis C, Baden LR, Hamel MB (2020) The Urgency of Care during the Covid-19 Pandemic - Learning as We Go, N Engl J Med, NEJMe2015903. [Google Scholar]
  • Aboud M, Kaplan R, Lombaard J (2019), Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis 19, 3, 253–264. [CrossRef] [PubMed] [Google Scholar]
  • Lim J, Jeon S, Shin HY, et al. (2020), Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: The application of Lopinavir/Ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 35, 6, e79. [CrossRef] [PubMed] [Google Scholar]
  • Rubin EJ, Harrington DP, Hogan JW, Gatsonis C, Baden LR, Hamel MB (2020), The Urgency of Care during the Covid-19 Pandemic – Learning as We Go. N Engl J Med 382, 25, 2461–2462. [Google Scholar]
  • McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C (2020), Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res 157, 104859. [CrossRef] [PubMed] [Google Scholar]
  • Zhao C, Li Y, Qiu W (2018), C5a induces A549 cell proliferation of non-small cell lung cancer via GDF15 gene activation mediated by GCN5-dependent KLF5 acetylation. Oncogene 37, 35, 4821–4837. [Google Scholar]
  • Tchesnokov EP, Feng JY, Porter DP, Götte M (2019), Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by Remdesivir. Viruses 11, 4, 326. [Google Scholar]
  • Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR (2020), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 55, 3, 105924. [CrossRef] [PubMed] [Google Scholar]
  • Li Z, Wang X, Cao D, Sun R, Li C, Li G (2020), Rapid review for the anti-coronavirus effect of remdesivir. Drug Discov Ther 14, 2, 73–76. [CrossRef] [PubMed] [Google Scholar]
  • Beigel JH, Tomashek KM, Dodd LE, et al. (2020), Remdesivir for the treatment of Covid-19 – preliminary report. N Engl J Med, [Google Scholar]
  • Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (2020), Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA 2020, [Google Scholar]
  • Atluri S, Manchikanti L, Hirsch JA (2020), Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: The Case for compassionate use. Pain Physician 23, 2, E71–E83. [PubMed] [Google Scholar]
  • McCreary EK, Pogue JM (2020), Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect Dis 7, 4, ofaa105. [CrossRef] [PubMed] [Google Scholar]
  • Wang Y, Zhang D, Du G (2020), Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 10236, 1569–1578. [Google Scholar]
  • Blaising J, Polyak SJ, Pécheur EI (2014), Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 107, 84–94. [CrossRef] [PubMed] [Google Scholar]
  • Haviernik J, Štefánik M, Fojtíková M (2018), Arbidol (Umifenovir): A broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses 10, 4, 184. [Google Scholar]
  • Zhang J, Xie M, Xia L (2018), Sublytic C5b–9 Induces IL-23 and IL-36a production by glomerular mesangial cells via PCAF-mediated KLF4 acetylation in rat Thy-1 nephritis. J Immunol 201, 11, 3184–3198. [CrossRef] [PubMed] [Google Scholar]
  • Wang CH, Zhong Y, Zhang Y (2016), A network analysis of the Chinese medicine Lianhua-Qingwen formula to identify its main effective components. Mol Biosyst 12, 2, 606–613. [Google Scholar]
  • Zhao P, Yang HZ, Lv HY, Wei ZM (2014), Efficacy of Lianhuaqingwen capsule compared with oseltamivir for influenza A virus infection: a meta-analysis of randomized, controlled trials. Altern Ther Health Med 20, 2, 25–30. [PubMed] [Google Scholar]
  • Ling XY, Tao JL, Sun X, Yuan B (2020), Exploring material basis and mechanism of Lianhua Qingwen Prescription against coronavirus based on network pharmacology. Zhong Cao Yao 51, 7, 1723–1730. [Google Scholar]
  • Wang FC, Shen BX, He CY, Zhao WC, Nie SL (2020), Clinical efficacy and mechanism of Lianhua Qingwen granule on COVID-19 based on network pharmacology research. Pharm Clin Chin Materia Medica 36, 2, 93–101. [Google Scholar]
  • Hu K, Guan WJ, Bi Y, et al. (2020), Efficacy and safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial. Phytomedicine 153242. [Google Scholar]
  • Du HX, Zhou HF, Wan HF (2018), Antiviral effects and mechanisms of Yinhuapinggan granule against H1N1 influenza virus infection in RAW264.7 cells. Inflammopharmacology 26, 6, 1455–1467. [CrossRef] [PubMed] [Google Scholar]
  • Peng XQ, Zhou HF, Lu YY, Chen JK, Wan HT, Zhang YY (2016), Protective effects of Yinhuapinggan granule on mice with influenza viral pneumonia. Int Immunopharmacol 30, 85–93. [Google Scholar]
  • Peng XQ, Zhou HF, Zhang YY, Yang JH, Wan HT, He Y (2016), Antiviral effects of Yinhuapinggan granule against influenza virus infection in the ICR mice model. J Nat Med 70, 1, 75–88. [CrossRef] [PubMed] [Google Scholar]
  • Li GQ, Zhao J, Tu ZT (2013), Treating influenza patients of wind-heat affecting Fei syndrome by Jinhua Qinggan granule: a double-blinded randomized control trial. Chin J Integr Trad West Med 33, 12, 1631–1635. [Google Scholar]
  • Lin JR, Zheng WW, Zeng GX, Lin QZ (2020), Study on the network pharmacology of Jinhua Qinggan granules in the treatment of COVID-19. Zhongyaocai 2020, 8, 2074–2080 [Google Scholar]
  • Zheng J, Xiang X, Xiao B, et al. (2018), Xuebijing combined with ulinastation benefits patients with sepsis: A meta-analysis. Am J Emerg Med 36, 3, 480–487. [Google Scholar]
  • Li J, Olaleye OE, Yu X, et al. (2019), High degree of pharmacokinetic compatibility exists between the five-herb medicine XueBiJing and antibiotics comedicated in sepsis care. Acta Pharm Sin B 9, 5, 1035–1049. [CrossRef] [PubMed] [Google Scholar]
  • Zhang CY, Zhang S, Wang W, Jiang XQ (2020), Clinical observation of Xuebijing in the treatment of COVID-19. Chin J Hosp Pharm 2020, 1–5. [Google Scholar]
  • Prompetchara E, Ketloy C, Palaga T (2020), Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 38, 1–9. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.